ArticleContemporary clinical trials communications2025
Assessing the efficacy of 3D window double screens (3D-WDS) in reducing malaria transmission in northeastern Tanzania: Study protocol for a two-arm cluster-randomised controlled trial.
Article in Contemporary clinical trials communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rise of insecticide resistance in malaria vectors has highlighted the urgent need for alternative vector control methods that do not rely on insecticides. The 3D-Screen, an innovative window screen featuring 3D conical structures integrated into a mesh, offers a promising solution. When installed as a double-screen setup (3D-Window Double Screen, or 3D-WDS) in window openings, its unidirectional design allows mosquitoes to enter the space between the screens from either the outside or inside of the living area, effectively trapping them within the enclosure. Previous laboratory and experimental hut studies have demonstrated the high efficacy of 3D-WDS in capturing host-seeking mosquitoes. This study aims to evaluate the epidemiological, entomological, and social impacts of implementing 3D-Screens in community settings. Methods/design: A two-arm, cluster-randomised controlled trial (cRCT) was conducted to assess whether houses equipped with both 3D-WDS and long-lasting insecticidal nets (LLINs) provide enhanced protection against malaria compared to LLINs alone. Twenty hamlets across 17 villages in Muheza, Tanzania, were evaluated for malaria prevalence, vector densities, entomological inoculation rates, and insecticide resistance levels. Fourteen hamlets with similar epidemiological and entomological profiles were then randomised: seven were assigned to the intervention group (3D-WDS + LLINs), and seven served as the control group (LLINs alone). Epidemiological and entomological surveillance were conducted at 10-week intervals over a 52-week follow-up period. Ancillary social science studies were conducted to assess community perceptions of the 3D-WDS intervention, focusing on acceptability and factors influencing its sustainability. Statistical analyses will use mixed-effects models to compare the impact of 3D-WDS combined with LLINs versus LLINs alone. Discussion: The 3D-WDS has the potential to reduce malaria transmission by providing a non-insecticidal, sustainable approach to mosquito control. Findings from this trial will demonstrate its real-world effectiveness and contribute to the development of scalable, long-term strategies for malaria prevention. Trial registration: ISRCTN Registry, ISRCTN87169034. Trial status: The study was initiated in June 2019, recruitment and sampling were completed in June 2021, sample analyses, and statistical evaluations are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.